Abstract
[This corrects the article DOI: 10.18632/oncotarget.16789.].
Highlights
Gallbladder cancer (GBC) is the most common malignancy of biliary system with low curative resection rate (10–30%), low response rate to chemotherapy, and poor prognosis (5-year survival less than 5%) [1, 2, 3]
We suggest that trophoblast cell surface antigen 2 (TROP2) could serve as a potential prognostic biomarker and therapeutic target for the clinical management of GBC
Overexpression of TROP2 was associated with poor prognosis of GBC
Summary
Gallbladder cancer (GBC) is the most common malignancy of biliary system with low curative resection rate (10–30%), low response rate to chemotherapy, and poor prognosis (5-year survival less than 5%) [1, 2, 3]. There is urgent need to reveal detailed signal pathways involved in GBC proliferation, migration and metastasis, which may provide potential prognostic biomarkers and therapeutic targets for the clinical management of GBC. TROP2 overexpression has been reported to be associated with poor survival, tumor aggressiveness and metastasis [6]. It was involved in many signaling pathways of cell proliferation, survival and self-renewal [14]. Liu et al found that TROP2 promoted the proliferation and invasion of cervical cancer cells by regulating ERK www.impactjournals.com/oncotarget signaling pathway [9]. We revealed that TROP2 promoted the proliferation, migration and metastasis of GBC cells by regulating PI3K/AKT pathway and inducing epithelial-mesenchymal transition (EMT). We suggest that TROP2 could serve as a potential prognostic biomarker and therapeutic target for the clinical management of GBC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
